Vaxcyte Inc

5VA

Company Profile

  • Business description

    Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

  • Contact

    825 Industrial Road
    Suite 300
    San CarlosCA94070
    USA

    T: +1 650 837-0111

    https://www.vaxcyte.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    507

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,071.4094.00-1.03%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,881.5521.01-0.19%
HKSE23,753.84116.240.49%
NASDAQ24,509.76626.52-2.49%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,260.1743.60-0.30%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2008,955.2089.50-0.99%
SSE Composite Index3,602.5731.78-0.87%

Market Movers